

**Preferred Drug List Committee
Meeting Agenda, Open Session
03/13/2019 11:30am to 1:00pm**

Meeting Location

DXC Technology (formerly HP Enterprise Services) Capital Room
6511 SE Forbes Ave., Bldg. 283 J, Topeka, Kansas 66619

Board Members

Taylor Gill, PharmD., BCPS
Wayne Wallace, M.D.
Raymond Magee, M.D.
Megan Hedden, PharmD.

Robert Haneke, PharmD
Jessica Bates, PharmD, BCPS
Donna Sweet, M.D.

KDHE-DHCF Staff

Annette Grant, RPh.
Victor Nguyen, PharmD

Markie O'Donnell, Transcriptionist

DXC Technology Staff

Karen Kluczykowski, RPh.

Kathy Kaesewurm, RN, BSN

MCO Staff

Angie Zhou, PharmD, **Sunflower State Health Plan**
Jennifer Murff, RPh, **UnitedHealthcare Community Plan**
Alan Carter, PharmD, **Aetna Better Health of Kansas**

I. Call to Order

1. Announcements and Introductions

II. Old Business

- 1. Review and Approval of June 13, 2018 Meeting Minutes**
- 2. Review and Approval of September 12, 2018 Meeting Minutes**

3. Consent Agenda Items

- i. PDL New Drug Placements
 - 1. Axid® Solution
 - 2. Evekeo® ODT
 - 3. Fycompa** Suspension
 - 4. Gabapentin** Solution
 - 5. Methylin® ER Tablets
 - 6. Novolin® 70/30 Flexpen™
 - 7. Onfi® Suspension
 - 8. Tagamet® Solution
 - 9. Zantac® Capsules
 - 10. Zantac® Solution
- ii. Committee discussion/Recommendations

III. New Business

- 1. Expanded Consent Agenda -Additional Pre-approval Request Criteria
 - a. If the new drug is a racemic mixture, a single enantiomer, diastereomer, or isomer of a current PDL drug.
 - b. Or, the new drug is a prodrug of a current PDL drug.
 - c. Or, the new drug includes the active ingredient moiety of a current PDL drug in the same PDL class/category but differs by brand name or manufacturer.
 - I. Public Comment*
 - II. Committee Discussion/Recommendations
- 2. Adjunct Anti-epileptics – Class Review – New Agent: (Sympazan™)
 - I. Public Comment*
 - II. Committee Discussion/Recommendations
- 3. Androgenic Agents – Class Review – New Agent: (Xyosted™)
 - I. Public Comment*
 - II. Committee Discussion/Recommendations
- 4. Anticholinergics for the Maintenance Treatment of COPD – Class Review – New Agent: (Yupelri™)
 - I. Public Comment*
 - II. Committee Discussion/Recommendations
- 5. Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists – New Class: (Aimovig™, Ajovy®, Emgality®)
 - I. Public Comment*
 - II. Committee Discussion/Recommendations

6. Corticosteroids – Ophthalmic – New Class: (Maxidex®, Durezol®, Flarex®, FML® Suspension/Liquifilm®/Ointment/Forte, Lotemax® Gel/Suspension/Ointment, Alrex®, Omnipred®, Pred Forte®, Pred Mild®)
 - I. Public Comment*
 - II. Committee Discussion/Recommendations
7. Corticosteroids – Topical – High Potency - Class Review – New Agent: (Bryhali™)
 - I. Public Comment*
 - II. Committee Discussion/Recommendations
8. Leukotriene Receptor Antagonists – New Class: (Accolate®, Singulair®, Zflo®, Zflo CR®)
 - I. Public Comment*
 - II. Committee Discussion/Recommendations
9. Prostaglandin Analogs – Class Review – New Agent: (Xelpros™)
 - I. Public Comment*
 - II. Committee Discussion/Recommendations

IV. Open Public Comment

V. Adjourn

The next PDL meeting is scheduled for June 12, 2019.

****THIS AGENDA IS SUBJECT TO CHANGE****